

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : To Be Assigned Confirmation No. :
First Named Inventor : Yuichi MURAYAMA, et al.
Filed : Concurrently Herewith
TC/A.U. : To Be Assigned
Examiner : To Be Assigned

Docket No. : 101551.55779US
Customer No. : 23911

Title : Method for Supressing Proliferation of Abnormal
Prion Protein

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a corresponding foreign Search Report citing such documents, together with an English-language version (if not already included) of that portion of the Search Report indicating the degree of relevance found by the foreign office. Copies of the references were supplied by the International Bureau.

10/520176


DT05 Rec'd PCT/PTO 05 JAN 2005

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. § 1.97(d)(2) and that the petition fee set forth in 37 C.F.R. § 1.17(i) in accordance with 37 C.F.R. § 1.97(d)(3) should be charged to Deposit Account 05-1323, Docket No.: 101551.55779US.

Respectfully submitted,

January 5, 2005


Herbert I. Canfor
Registration No. 24,392

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
HIC:vgp

10/520176

605 Rec'd PCT/PTO Sheet of 1 JAN 2005

FORM PTO-1449 U.S. Department of Commerce Patent & Trademark Office INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Attorney Docket No. 101551.55779US	Serial No. To Be Assigned
		Applicant: Yuuichi MURAYAMA et al.	
		Filing Date Concurrently Herewith	Group To Be Assigned

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA	5,919,823	7/6/1999	Richardson			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	TRANSLATION
							Yes No
	AK	WO 96 21437	7/18/1996	New York State Office of Menta			
	AL	EP 0 764 442	3/26/1997	Holt John Alfred Gorton			
	AM	EP 0 824 919	2/25/1998	Holt John Alfred Gorton			
	AN	WO 00 64420	11/2/2000	Neurochem Inc.			
	AO	WO 01 26623	4/19/2001	Laxdale Ltd.			
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	AQ	Callebaut, Isabelle et al., "Common prevalence of alanine and glycine in mobile reaction center loops of serpins and viral fusion peptides: do prions possess a fusio peptide?", Journal of Computer-Aided Molecular Design, (1994), 8(2), 175-91.
	AR	Database WPI, Section Ch. Week 200264, Derwent Publications Ltd., AN 2002-599522, XP-002236107 & WO 02 49638 A (Ajinomoto KK), June 27, 2002 abstract.
	AS	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.	